175 related articles for article (PubMed ID: 29996687)
1. Porous silicon based intravitreal platform for dual-drug loading and controlled release towards synergistic therapy.
Warther D; Xiao Y; Li F; Wang Y; Huffman K; Freeman WR; Sailor M; Cheng L
Drug Deliv; 2018 Nov; 25(1):1537-1545. PubMed ID: 29996687
[TBL] [Abstract][Full Text] [Related]
2. A sustained dual drug delivery system for proliferative vitreoretinopathy.
Xiao Y; Choi KS; Warther D; Huffman K; Landeros S; Freeman WR; Sailor MJ; Cheng L
Drug Deliv; 2020 Dec; 27(1):1461-1473. PubMed ID: 33100053
[TBL] [Abstract][Full Text] [Related]
3. Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon.
Hou H; Nieto A; Ma F; Freeman WR; Sailor MJ; Cheng L
J Control Release; 2014 Mar; 178():46-54. PubMed ID: 24424270
[TBL] [Abstract][Full Text] [Related]
4. Controlled Release of Dexamethasone From an Intravitreal Delivery System Using Porous Silicon Dioxide.
Hou H; Wang C; Nan K; Freeman WR; Sailor MJ; Cheng L
Invest Ophthalmol Vis Sci; 2016 Feb; 57(2):557-66. PubMed ID: 26882530
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal controlled release of dexamethasone from engineered microparticles of porous silicon dioxide.
Wang C; Hou H; Nan K; Sailor MJ; Freeman WR; Cheng L
Exp Eye Res; 2014 Dec; 129():74-82. PubMed ID: 25446320
[TBL] [Abstract][Full Text] [Related]
6. Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system.
Chhablani J; Nieto A; Hou H; Wu EC; Freeman WR; Sailor MJ; Cheng L
Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):1268-79. PubMed ID: 23322571
[TBL] [Abstract][Full Text] [Related]
7. Hydrosilylated porous silicon particles function as an intravitreal drug delivery system for daunorubicin.
Hartmann KI; Nieto A; Wu EC; Freeman WR; Kim JS; Chhablani J; Sailor MJ; Cheng L
J Ocul Pharmacol Ther; 2013 Jun; 29(5):493-500. PubMed ID: 23448595
[TBL] [Abstract][Full Text] [Related]
8. A Novel Approach of Daunorubicin Application on Formation of Proliferative Retinopathy Using a Porous Silicon Controlled Delivery System: Pharmacodynamics.
Hou H; Huffman K; Rios S; Freeman WR; Sailor MJ; Cheng L
Invest Ophthalmol Vis Sci; 2015 Apr; 56(4):2755-63. PubMed ID: 25829415
[TBL] [Abstract][Full Text] [Related]
9. A preliminary evaluation of dexamethasone palmitate emulsion: a novel intravitreal sustained delivery of corticosteroid for treatment of macular edema.
Daull P; Paterson CA; Kuppermann BD; Garrigue JS
J Ocul Pharmacol Ther; 2013 Mar; 29(2):258-69. PubMed ID: 23331052
[TBL] [Abstract][Full Text] [Related]
10. New model of proliferative vitreoretinopathy in rabbit for drug delivery and pharmacodynamic studies.
Moon SW; Sun Y; Warther D; Huffman K; Freeman WR; Sailor MJ; Cheng L
Drug Deliv; 2018 Jan; 25(1):600-610. PubMed ID: 29461171
[TBL] [Abstract][Full Text] [Related]
11. Porous silicon oxide-PLGA composite microspheres for sustained ocular delivery of daunorubicin.
Nan K; Ma F; Hou H; Freeman WR; Sailor MJ; Cheng L
Acta Biomater; 2014 Aug; 10(8):3505-12. PubMed ID: 24793657
[TBL] [Abstract][Full Text] [Related]
12. Surface engineering of porous silicon microparticles for intravitreal sustained delivery of rapamycin.
Nieto A; Hou H; Moon SW; Sailor MJ; Freeman WR; Cheng L
Invest Ophthalmol Vis Sci; 2015 Jan; 56(2):1070-80. PubMed ID: 25613937
[TBL] [Abstract][Full Text] [Related]
13. A sustained intravitreal drug delivery system with remote real time monitoring capability.
Hou H; Nieto A; Belghith A; Nan K; Li Y; Freeman WR; Sailor MJ; Cheng L
Acta Biomater; 2015 Sep; 24():309-21. PubMed ID: 26087110
[TBL] [Abstract][Full Text] [Related]
14. Ocular silicon distribution and clearance following intravitreal injection of porous silicon microparticles.
Nieto A; Hou H; Sailor MJ; Freeman WR; Cheng L
Exp Eye Res; 2013 Nov; 116():161-8. PubMed ID: 24036388
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and tolerance study of intravitreal injection of dexamethasone-loaded nanoparticles in rabbits.
Zhang L; Li Y; Zhang C; Wang Y; Song C
Int J Nanomedicine; 2009; 4():175-83. PubMed ID: 19774116
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of endotoxin-induced uveitis by intravitreal injection of polylactic-glycolic acid (PLGA) microspheres loaded with dexamethasone.
Barcia E; Herrero-Vanrell R; Díez A; Alvarez-Santiago C; López I; Calonge M
Exp Eye Res; 2009 Aug; 89(2):238-45. PubMed ID: 19341729
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal properties of porous silicon photonic crystals: a potential self-reporting intraocular drug-delivery vehicle.
Cheng L; Anglin E; Cunin F; Kim D; Sailor MJ; Falkenstein I; Tammewar A; Freeman WR
Br J Ophthalmol; 2008 May; 92(5):705-11. PubMed ID: 18441177
[TBL] [Abstract][Full Text] [Related]
18. Dual-drug delivery by porous silicon nanoparticles for improved cellular uptake, sustained release, and combination therapy.
Wang CF; Mäkilä EM; Kaasalainen MH; Hagström MV; Salonen JJ; Hirvonen JT; Santos HA
Acta Biomater; 2015 Apr; 16():206-14. PubMed ID: 25637067
[TBL] [Abstract][Full Text] [Related]
19. [Intravitreally injectable poly (D, L-Lactide) microspheres containing dexamethasone acetate for sustained release].
Wu W; Yang X; Lu B
Yao Xue Xue Bao; 2001 Oct; 36(10):766-70. PubMed ID: 12579978
[TBL] [Abstract][Full Text] [Related]
20. Controllable continuous sub-tenon drug delivery of dexamethasone disodium phosphate to ocular posterior segment in rabbit.
Huang X; Liu S; Yang Y; Duan Y; Lin D
Drug Deliv; 2017 Nov; 24(1):452-458. PubMed ID: 28165816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
